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ABSTRACT
Liposarcoma is a common subtype of soft tissue sarcoma and accounts for 
20% of all sarcomas. Conventional chemotherapeutic agents have limited efficacy 
in liposarcoma patients. Expression and activation of serine/threonine-protein 
kinase dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1B (DYRK1B) 
is associated with growth and survival of many types of cancer cells. However, the 
role of DYRK1B in liposarcoma remains unknown. In this study, we investigated the 
functional and therapeutic relevance of DYRK1B in liposarcoma. Tissue microarray 
and immunohistochemistry analysis showed that higher expression levels of DYRK1B 
correlated with a worse prognosis. RNA interference-mediated knockdown of DYRK1B 
or targeting DYRK1B with the kinase inhibitor AZ191 inhibited liposarcoma cell 
growth, decreased cell motility, and induced apoptosis. Moreover, combined AZ191 
with doxorubicin demonstrated an increased anti-cancer effect on liposarcoma cells. 
These findings suggest that DYRK1B is critical for the growth of liposarcoma cells. 
Targeting DYRK1B provides a new rationale for treatment of liposarcoma.
INTRODUCTION
Liposarcoma is a malignant tumor that arises in the 
body’s fat cells of the soft tissues. Liposarcoma represents 
the second most common soft tissue sarcoma and makes 
up approximately 20% of all sarcomas in adults. This 
disease occurs most frequently in middle-aged and older 
adults (age 40 and above), and its predilection sites include 
the thigh or the retroperitoneum. The classification of soft 
tissue and bone tumors by the World Health Organization 
(WHO) in 2013 distinguished four major liposarcoma 
subtypes: (i) well-differentiated liposarcoma (45% of all 
liposarcomas); (ii) de-differentiated liposarcoma (5% of 
all liposarcomas); (iii) myxoid liposarcoma (35% of all 
liposarcomas); and (iv) pleomorphic liposarcoma (15% 
of all liposarcomas) [1]. Like other soft tissue sarcomas, 
a wide resection is the primary standard of treatment 
for liposarcoma patients, combined with radiotherapy 
or chemotherapy. Although doxorubicin and ifosfamide 
have been used for treatment of advanced or metastatic 
liposarcoma patients for over 30 years, the benefit 
of chemotherapeutic drugs on survival of metastatic 
liposarcoma remains controversial [2–4]. The five-year 
survival rate for patients with high-grade liposarcoma is 
less than 50% [5]. Therefore, there is an urgent need to 
identify new treatment strategies to improve the outcomes 
of patients with liposarcoma. 
The human genome contains at least 600 protein 
kinases that phosphorylate proteins at more than 250,000 
sites. Abnormal expression or activation of certain protein 
kinases involved in tumor cell growth, proliferation, 
apoptosis, and drug sensitivity [6, 7]. Consequently, 
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protein kinases have emerged as one of the most 
promising therapeutic target families for the treatment 
of cancers. To date, the Food and Drug Administration 
(FDA) has approved over 35 protein kinases inhibitors for 
clinical use [8]. Several protein kinases have been found 
to be overexpressed or highly activated in liposarcoma, 
including the proto-oncogenes phosphatidylinositol 
3-kinase (PI3K)/AKT, cyclin-dependent kinase 4 (CDK4), 
and CDK11 [9–11]. Amplification and upregulation of 
these kinase pathways are thought to be an early and 
essential part of the oncogenic program of liposarcoma. 
For example, CDK4 is amplified in patients with 
well-differentiated liposarcoma and de-differentiated 
liposarcoma, hepatocyte growth factor receptor (MET) 
is overexpressed in de-differentiated liposarcoma, and 
SRC is activated in myxoid liposarcoma and pleomorphic 
liposarcoma [12–14]. Recently, clinical trials were 
conducted to target protein kinases in liposarcoma, 
including CDK4 inhibitor palbociclib (PD0332991), pan-
CDK inhibitor flavopiridol, vascular endothelial growth 
factor receptor (VEGFR) inhibitor sorafenib, multi-kinase 
inhibitor regorafenib, and vascular endothelial growth 
factor A (VEGF-A) monoclonal antibody bevacizumab 
[15–19]. 
DYRK1B (also known as Mirk) belongs to the 
DYRK family of protein kinases, which include five 
conserved members, DYRK1A, DYRK1B, DYRK2, 
DYRK3, and DYRK4. DYRKs are dual function kinases 
family with the ability to auto-phosphorylate themselves 
on tyrosine during translation, and then phosphorylate 
other substrates on serine and threonine residues. DYRKs 
play key roles in the regulation of cell differentiation, 
proliferation, and survival, as well as cell-cycle control 
[20]. DYRK1B is mainly highly expressed in skeletal 
muscle and in the testis and is detected at low levels in 
most other normal tissues. DYRK1B facilitates skeletal 
myoblast differentiation and survival by mediating 
cell cycle arrested in G0 phase and exerting anti-
apoptotic effect [21, 22]. More importantly, DYRK1B 
is overexpressed and highly activated in many types of 
solid tumors, including pancreatic, lung, ovarian, colon 
cancer, rhabdomyosarcoma and osteosarcoma [23–28]. 
On the other hand, emerging insights into DYRK1B 
promotion adipogenesis and involvement in metabolic 
syndrome suggest that DYRK1B may potentially 
relevant to fat cell malignancy [29]. Moreover, the roles 
of DYRK1B in liposarcoma and the significance of 
targeting DYRK1B signaling as a putative therapeutic 
remain unknown. Therefore, in the present study, we 
performed an immunohistochemistry (IHC) assay to 
examine the expression of DYRK1B in a microarray 
of liposarcoma patient tissues. We further evaluated the 
function of DYRK1B in the proliferation and motility of 
liposarcoma cells. In addition, we determined the effect 
of the combination of doxorubicin with DYRK1B kinase 
inhibitor AZ191 on liposarcoma cells. 
RESULTS
DYRK1B is overexpressed in human 
liposarcoma as compared with lipoma tissues 
We examined the expression of DYRK1B by IHC 
using a human lipomatous tumor tissue microarray (TMA) 
and human normal tonsil tissue as control (Figure 1 and 
Supplementary Figure 1). Seventeen and 42 patients with 
pathological diagnosis of lipoma and liposarcoma were 
identified, respectively (Table 1). DYRK1B staining 
intensity was graded into four groups: 0 (negative 
staining), 1+ (low staining), 2+ (moderate staining), and 
3+ (high staining). The summary of the clinicopathologic 
characteristics of patients with liposarcoma is shown 
in Table 2. The results demonstrated that the level of 
DYRK1B expression were higher in patients with 
liposarcoma than lipoma patients. In addition, the 
results also showed that the DYRK1B protein was 
predominantly localized in the cytoplasm of liposarcoma 
cells (Figure 1A). 
Expression of DYRK1B is associated with poor 
prognosis in patients with liposarcoma 
To explore the relationship between DYRK1B 
expression and clinical prognosis, we evaluated DYRK1B 
staining in liposarcoma patient specimens. Kaplan-Meier 
survival analysis showed that the prognosis for liposarcoma 
patients with high DYRK1B staining was significantly 
worse than those with negative/low DYRK1B staining 
group (Figure 1B). With respect to clinical characteristics, 
liposarcomas are classified into four pathology subtypes. 
Therefore, we compared DYRK1B staining intensity 
between the four groups: well-differentiated liposarcoma, 
de-differentiated liposarcoma, myxoid liposarcoma, and 
pleomorphic liposarcoma (Table 2). Overall survival 
for patients with well-differentiated liposarcoma was 
significantly better than the de-differentiated liposarcoma 
patients, myxoid liposarcoma, and pleomorphic 
liposarcoma, respectively (Figure 1C). 
DYRK1B is crucial for liposarcoma cell growth 
and survival 
To characterize the functional role of DYRK1B 
in liposarcoma, we investigated the inhibition effect 
of DYRK1B in liposarcoma by small molecule kinase 
inhibitor AZ191 and RNAi. AZ191 is a novel selective 
DYRK1B kinase inhibitor [30]. To determine the 
specific inhibitory effects of DYRK1B on liposarcoma 
cells in vitro, we treated both SW872 and SW982 
liposarcoma cell lines with increasing concentrations 
(0.01–60 μM) of AZ191 for five days and subsequently 
examined cell viability by 3-(4, 5-dimethylthiazolyl-2)-2, 
5-diphenyltetrazolium bromide (MTT) assay. The 
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inhibition of cell viability effects were observed in both 
cell lines (Figure 2A and 2B). There was dose-dependent 
growth inhibition with AZ191 treatment in SW872 
(IC50 = 3.183 μM) and SW982 (IC50 = 1.279 μM) cell 
lines. Clonogenicity is a reflection of in vitro cell survival 
based on the ability of a single cancer cell to grow into a 
colony [31]. To assess the effect of DYRK1B inhibition 
on survival and proliferation capacity of liposarcoma cells, 
cells were incubated with 3 μM AZ191 for 1–2 weeks. As 
shown in Figure 2C and 2D, both SW872 and SW982 cells 
colony formation capacities were significantly decreased 
after treatment with AZ191. 
To determine the effect of DYRK1B knockdown on 
liposarcoma cell growth in vitro, we transfected synthetic 
DYRK1B siRNA into SW872 and SW982 cell lines. After 
incubation with DYRK1B siRNA or non-specific siRNA 
at concentrations ranging from 10 to 80 nM for five days, 
the MTT assay showed that siRNA-mediated knockdown 
of DYRK1B significantly reduced liposarcoma cell 
viability in both cell lines in a dose-dependent manner 
(Figure 2E). 
To further confirm the effect of DYRK1B 
knockdown on liposarcoma cells, we also applied 
DYRK1B targeted endoribonuclease-prepared siRNA 
(esiRNA) in liposarcoma cell lines. esiRNAs are 
synthesized by in vitro transcription of a 300–600 bp 
gene specific double-stranded RNA (dsRNA), followed 
by enzymatic digestion using RNases (i.e., RNase 
III). esiRNAs have the advantage of lower off-target 
effects as compared with siRNA [32]. Similar results 
to the siRNA treatment were obtained with DYRK1B 
esiRNA (concentration gradient ranged from 10 to 80 
nM for five days) in both SW872 and SW982 cell lines 
(Figure 2F). Downregulated expression of DYRK1B 
was confirmed by Western blot after DYRK1B siRNA 
or esiRNA transfection for 48 hours (Figure 3A–3D). In 
addition, two DYRK1B blot bands were detected. The 
molecular weight was around 70 kDa and 67 kDa, in line 
with previous studies [33, 34]. The level of DYRK1B 
expression was suppressed by DYRK1B targeted RNAi in 
a dose-dependent manner, as determined by densitometry 
quantification. These results demonstrate that DYRK1B is 
vital to promote cell growth and viability in liposarcoma 
cells. 
Inhibition of DYRK1B suppresses liposarcoma 
cell motility 
Tumor cell motility is important for cancer 
invasion and metastasis. We next investigated the effect 
of DYRK1B inhibition on the abilities of liposarcoma 
cell migration and invasion. Wound healing assays were 
performed after treatment with AZ191, DYRK1B siRNA, 
or esiRNA. Relative cell migration distance was evaluated 
at 0, 8, 24, and 48 hours, respectively, after treatment by 
the scratch assay as described. We observed a marked 
inhibition of migratory potential in both SW872 and 
SW982 cell lines compared with control or non-specific 
Figure 1: DYRK1B is overexpressed in liposarcoma and correlates with poor patient prognosis. (A) Representative images 
of cytoplasmic staining intensity of DYRK1B staining in human lipomatous tumor tissues. Original magnification: 100× and 400×. Scale 
bar = 100μm (upper 100× photos) or 25 μm (lower 400× photos). (B) Correlation between expression of DYRK1B (negative/low staining, 
moderate staining, and high staining) and overall survival in liposarcoma patients. (C) Four liposarcoma pathology subtypes patients (well-
differentiated liposarcoma, de-differentiated liposarcoma, myxoid liposarcoma, and pleomorphic liposarcoma) distributed on the Kaplan-
Meier survival curve.
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siRNA groups, especially at higher concentrations groups 
(Figure 4A–4D and Supplementary Figure 2A–2C). 
Wounds were almost fully recovered after the 48-hour 
migration in blank control and non-specific siRNA treated 
cells. Similarly, in transwell invasion chamber assays, 
SW872 cell invasion ability was significantly reduced 
compare with control cells after treatment with AZ191 
3 μM for 48 hours (P < 0.05, Figure 4E and 4F). These 
data demonstrate that inhibition of DYRK1B impaired 
liposarcoma cell motility capability. 
DYRK1B inhibition induces apoptosis in 
liposarcoma cells 
To assess whether the observed growth inhibitory 
effect induced by DYRK1B inhibition on liposarcoma 
cells was due to an induction of apoptosis, we performed 
flow cytometric analysis and Western blot assays. 
Following 48 hours of treatment with 1 μM, 2 μM, and 
4 μM AZ191 as described, both liposarcoma cell lines 
showed significantly increased rates of apoptosis in 
a dose-dependent fashion as compared with dimethyl 
sulfoxide (DMSO) treated cells, which were used as 
negative controls (Figure 5A and 5B). 
Then, we conducted Western blot assays on cell 
extracts by treatment with increasing concentrations of 
AZ191 or DYRK1B siRNA after 48 hours. The Western 
blot assay showed that targeting DYRK1B with AZ191 
did not alter the expression of DYRK1B protein levels 
(Figure 5C), which is consistent with previous literature 
[30]. Several apoptotic related proteins were assessed. As 
shown in Figure 5C, downregulation of three anti-apoptotic 
proteins (Bcl-2, p21, and survivin) were observed at higher 
concentrations of AZ191 treated cells as compared with 
controls. Similar results were obtained in DYRK1B siRNA 
transfected liposarcoma cell lines (Figure 5D). 
DYRK1B inhibition increases anti-cancer effects 
of doxorubicin 
To determine the effects of combinations of conventional 
chemotherapy agent doxorubicin and DYRK1B targeted 
therapy on the growth of liposarcoma cells, both SW872 
and SW982 cells were co-treated with increasing doses of 
doxorubicin and AZ191 for five days. As shown by MTT 
analysis, the combination of doxorubicin with AZ191 increased 
anti-cancer effects on both liposarcoma cell lines (Figure 6). 
DISCUSSION
In the present study, we demonstrated for the 
first time the crucial role of DYRK1B in liposarcoma. 
Table 1: Characteristics of the lipomatous tumors patients
Factors No. (%)
Age
 < 40 years old
 ≥ 40 years old
Gender (n = 59)
 Female
 Male
Pathology (n = 59)
 Lipoma
 Liposarcoma, well differentiated
 Liposarcoma, dedifferentiated
 Liposarcoma, myxoid
 Liposarcoma, pleomorphic
Survival (Liposarcoma n = 42)
 Alive
 Deceased
Tumor Location (Liposarcoma n = 42)
 neck/chest/abdomen/buttock
 mediastinum
 abdominal cavity
 retroperitoneal
 Extremities
Expression of DYRK1B
 Lipoma (n = 17)
 Liposarcoma (n = 42)
9 (15.3%)
50 (84.7%)
26 (44.1%)
33 (55.9%)
17 (28.8%)
19 (32.2%)
5 (8.5%)
15 (25.4%)
3 (5.1%)
24 (57.1%)
18 (42.9%)
5 (11.9%)
1 (2.4%)
10 (23.8%)
11 (26.2%)
15 (35.7%)
0  1+  2+  3+
13 (76.5%) 3 (17.6%) 1 (5.9%) 
9 (21.4%) 13 (31%) 9 (21.4%) 11 (26.2%)
Note: 0 (negative staining); 1+ (low staining); 2+ (moderate staining); 3+ (high staining).
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It has been previously demonstrated that DYRK1B 
was classified into DYRK1B-p65, DYRK1B-p69 and 
DYRK1B-p75 three splicing variants subtypes with 
different expression patterns and protein kinases activities 
[33]. Moreover, it is proposed that DYRK1B-p65 and 
DYRK1B-p69 quite probably correspond to DYRK1B 
70 kDa and 67 kDa described by earlier report [34]. 
More importantly, the previous study described that 
undifferentiated 3T3-L1 preadipocytes contained only 
DYRK1B-p65 and DYRK1B-p69. This result seems likely 
that there may be a relationship between DYRK1B and 
liposarcoma since liposarcoma is considered a malignant 
tumor arises in the fat cells. Our findings demonstrated 
the DYRK1B protein is overexpressed in the majority 
of liposarcoma patient specimens as compared with 
lipoma tissues by IHC analysis. We then examined the 
association between the level of DYRK1B expression 
and the prognostic significance of pathology subtype 
in liposarcomas. We also demonstrated that higher 
expression of DYRK1B is correlated with worse prognosis 
in liposarcoma. Kaplan-Meier survival curve analysis 
showed that well-differentiated liposarcoma patients have 
a better prognosis than other pathology subtypes [35]. 
These findings validate previous reports that amplified 
expression of DYRK1B is involved in the progression 
of certain cancers and associated with poor prognosis 
[36–40]. We then investigated the function roles of 
DYRK1B in liposarcoma cells. By targeting with small 
molecule kinase inhibitor AZ191 or RNAi-mediated 
knockdown, we observed reduction of proliferation, 
as well as suppression of cell motility, induction of 
apoptosis, and sensitization to chemotherapy drug in 
liposarcoma cells. These findings indicate that DYRK1B 
could play a significant role in liposarcoma cell growth 
and proliferation. 
We then investigated the potential mechanism of 
inhibition of DYRK1B on the growth of liposarcoma 
cells. Several small molecule DYRK1B kinase inhibitors 
Figure 2: Inhibition of DYRK1B by kinase inhibitor AZ191 or RNAi blocks proliferation in liposarcoma cell lines. 
(A) Inhibition of cell proliferation after DYRK1B inhibitor AZ191 treatment of SW872 and SW982 cell lines as determined by the MTT 
assay. (B) Representative images of liposarcoma cells after treatment with increasing concentrations of DYRK1B inhibitor AZ191. Original 
magnification: 100×. Scale bar = 100 μm. (C) Representative images of liposarcoma cell colony formation after treatment with AZ191. 
(D) Inhibition of cell colony formation rate after AZ191 treatment of SW872 and SW982 cells determined by the clonogenic assay. (E) 
Inhibition of cell proliferation after DYRK1B siRNA transfection in SW872 and SW982 cell lines as determined by the MTT assay. (F) 
Inhibition of cell proliferation after DYRK1B esiRNA transfection in SW872 and SW982 cell lines as determined by the MTT assay. Data 
were shown as means ± S.D.
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have been studied in preclinical cancer researches, 
including DYRKi in pancreatic cancer, and EHT5372 
in pancreatic cancer and ovarian cancer [40–42]. We 
recruited DYRK1B kinase inhibitor AZ191 to block 
DYRK1B kinases activity, which has been validated in 
pancreatic and ovarian cancer cells before [43]. AZ191 has 
been shown to exhibit 10-fold selectivity for DYRK1B 
over DYRK1A [30]. As demonstrated by flow cytometric 
analysis, AZ191 induced apoptosis in both liposarcoma 
cell lines in a dose-dependent manner. Expression of anti-
apoptotic proteins, including Bcl-2, p21, and survivin, 
were decreased after treatment with AZ191, suggesting 
that DYRK1B is involved in apoptosis signaling. Bcl-
2 is the founding member of the Bcl-2 family—a well-
established key regulator of the apoptosis gene family. 
Bcl-2 exerts a cell survival function in response to 
apoptotic stimuli through inhibition of mitochondrial 
cytochrome C release, which subsequently activates 
caspase and Poly(ADP-ribose) polymerase (PARP) 
cleavage in the intrinsic apoptosis pathway [44]. Our 
finding was consistent with a previous report describing 
that downregulation of Bcl-2 was involved in apoptosis 
in SW872 cells [45]. Survivin belongs to the inhibitor of 
apoptosis (IAP) family and has anti-apoptosis function by 
directly binding and inhibiting caspase-3 activation, which 
serves as a critical effector of apoptosis [46]. Elevated 
survivin also was reported in soft tissue sarcoma, including 
liposarcoma, and inverse correlated with prognosis [47]. 
Depending on intracellular localization, p21 plays a role 
in cell cycle arrest as a potent inhibitor of apoptosis, which 
is also involved in p53 mediated apoptosis and interaction 
with procaspase-3 and cyclin A/CDK2 complexes 
[48, 49]. More interestingly, DYRK1B can phosphorylate 
p21 at Ser153 and drive p21 translocation to the cytoplasm, 
which subsequently enables p21 to block apoptosis 
[22, 50]. In addition, DYRK1B also promotes the 
expression of p21 [30]. In line with these findings, we 
observed that AZ191 reduced the expression of p21 in 
liposarcoma cells associated with increased apoptosis. 
To further confirm the effects of inhibition 
DYRK1B in liposarcoma, we compared transfection with 
DYRK1B siRNA to SW872 and SW982 liposarcoma cell 
lines. Knockdown of DYRK1B by siRNA also resulted 
in decreased Bcl-2, p21, and survivin. Moreover, PARP 
cleavage was detected by knockdown of DYRK1B. 
These data further validate the molecular mechanism 
for transfection of DYRK1B siRNA induced apoptosis 
in liposarcoma. Taken together, as shown in Figure 7, 
Figure 3: DYRK1B protein expression after treatment of liposarcoma cell lines with DYRK1B siRNA or esiRNA as 
determined by Western blot. (A and B) Knockdown of DYRK1B protein expression after DYRK1B siRNA transfection in SW872 and 
SW982 cell lines as determined by Western blot and semi-quantitative analysis. (C and D) Confirmation of knockdown of DYRK1B protein 
expression after DYRK1B esiRNA transfection in SW872 and SW982 cell lines as determined by Western blot and semi-quantitative 
analysis. Molecular size marker 75kDa is shown at the left.
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Table 2: Summary of the clinicopathological characteristics of lipomatous tumors patients
Clinicopathological feature No.    DYRK1B expression
Negative/Low staining Moderate staining high staining p value
Pathology 
Lipoma           17
Liposarcoma   42
Age (liposarcoma, n = 42)
< 40 years old   7
≥ 40 years old   35
Gender (liposarcoma, n = 42)
Female    21
Male    21
Pathology (liposarcoma, n = 42)
well differentiated  19
dedifferentiated   5
myxoid    15
pleomorphic   3
 16   1   0 0.0089
 22   9    11
 4   1   2  0.8805 
 18   8   9 
 13   4   4  0.4368
 9   5   7
 18   1    0 0.0001
 1    3   1
 2   4    9
 1   1   1
Figure 4: Inhibition of DYRK1B by kinase inhibitor AZ191 or RNAi impairs motility in liposarcoma cell lines. (A) 
Representative migration images of SW872 cell lines at different time points (0, 8, 24, and 48 hours) when treated with different concentrations 
of AZ191. Original magnification: 100×. Scale bar = 100 μm. (B) Relative migration distance of SW872 and SW982 at different time points (0, 
8, 24, and 48 hours) when treated with different concentrations of AZ191. (C) Relative migration distance of SW872 and SW982 at different 
time points (0, 8, 24, and 48 hours) when treated with different concentrations of DYRK1B siRNA and non-specific siRNA. (D) Confirmation of 
relative migration distance of SW872 and SW982 at different time points (0, 8, 24, and 48 hours) when treated with different concentrations of 
DYRK1B esiRNA and non-specific siRNA. (E and F) Representative invasion images and number of invasion SW872 cells through the Matrigel 
after treatment with DMSO or AZ191 3 μM for 48 hours. Original magnification: 200×. Scale bar = 50 μm. Data were shown as means ± S.D.
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our study suggests that inhibition of DYRK1B with 
RNAi or a specific kinase inhibitor AZ191 suppresses 
cell proliferation and induces apoptosis through the 
downregualtion of anti-apoptotic proteins in liposarcoma. 
Finally, we found that inhibition of DYRK1B with 
AZ191 enhanced the cytotoxic effect of doxorubicin in 
liposarcoma cells, which is consistent with previous 
reports that DYRK1B inhibitor sensitized both ovarian 
cancer cell lines and patient ascites derived primary cells 
to chemotherapy drug cisplatin [42, 51]. This data suggests 
that a combination therapy of DYRK1B inhibition and 
chemotherapy drug could be considered for clinical trials 
as a potent treatment for liposarcoma patients. 
In summary, our study revealed that DYRK1B is 
overexpressed in liposarcoma. High expression of DYRK1B 
is associated with poor outcomes, which may serve as 
a prognostic and predictive biomarker in liposarcoma 
patients. Inhibition of DYRK1B resulted in significantly 
decreased cell growth and motility in liposarcoma. This 
effect was enhanced when combined with doxorubicin. 
Future in vivo studies and molecular mechanisms of 
DYRK1B in liposarcoma should be explored. 
MATERIALS AND METHODS
Tissue Microarray (TMA) and 
immunohistochemistry (IHC)
The conditions of DYRK1B IHC were first 
evaluated and optimized in human normal tonsil 
tissues with the rabbit polyclonal antibody to human 
DYRK1B, which was kindly provided by Dr Xiaobing 
Deng and Ying Huang from State University of New 
York, Syracuse, New York. Normal tonsil showed low 
expression of DYRK1B (Supplementary Figure 1). 
The human liposarcoma and lipoma tissue array was 
purchased from Novus Biologicals, LLC (Littleton, CO, 
USA) and were used in accordance with the policies 
of the institutional review board of the Massachusetts 
General Hospital (IRB protocol # 2007P-002464), which 
contains 59 samples from 59 lipomatous tumors patients, 
and included clinicopathological data on age, sex, 
location, diagnosis, tumor tissue pathological subtypes, 
follow-up months, follow-up result, and cause of death. 
The expression level of DYRK1B was determined based 
Figure 5: Inhibition of DYRK1B by kinase inhibitor AZ191 or siRNA transfection induces cell apoptosis in liposarcoma 
cell lines. (A) Representative results of flow cytometric analysis cell apoptosis of SW872 and SW982 cell lines, incubated with different 
concentrations of AZ191 or DMSO. (B) Analysis of apoptosis rate of SW872 and SW982 cell lines treated with different concentrations 
of AZ191 or DMSO. (C) Representative Western blot analysis of apoptosis-related proteins alterations in SW872 and SW982 cell lines 
after treatment with different concentrations of AZ191. (D) Representative Western blot analysis of apoptosis-related proteins alterations 
in SW872 and SW982 cell lines after transfection of different concentrations of DYRK1B siRNA and non-specific siRNA. Molecular size 
marker 75kDa is shown at the left. Data were shown as means ± S.D. 
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on the Immunohistochemistry Protocol (Paraffin) from 
Cell Signaling Technology (Danvers, MA, USA). Briefly, 
paraffin embedded slide was baked at 60°C for 1 hour. 
Sections were washed three times in xylene for 5 min 
each, and then transferred through graded ethanol (100% 
and 95%) twice for rehydration for 10 minutes each. 
Following the process of antigen retrieval, endogenous 
peroxidase activity was quenched by incubation in 3% 
hydrogen peroxide. After protein blocking with normal 
goat serum for 1 hour at room temperature, the DYRK1B 
primary antibody (1:50 dilution) was applied at 4°C 
overnight in a humidified chamber. The bound antibody 
on the array was detected by using SignalStain® Boost 
Detection Reagent (Cell Signaling Technology, Danvers, 
MA, USA) and SignalStain® DAB (Cell Signaling 
Technology, Danvers, MA, USA). Prior to imaging, the 
section was counterstained with hematoxylin QS (Vector 
Laboratories, CA, USA) and mounted with VectaMount 
AQ (Vector Laboratories, CA, USA) coverslip for long-
term preservation. 
The degree of immunostaining on the tissue 
array was viewed and scored separately by two 
independent investigators who had no knowledge of the 
histopathological features or patient details of the samples. 
Any differences in the scores were resolved by consensus 
after joint review of the slides and discussion between the 
two investigators. The immunostaining intensity pattern 
of DYRK1B was assessed on a scale semi-quantitatively 
as follows: 0, negative staining; 1+, low staining; 2+, 
moderate staining; and 3+, high staining. 
Cell lines and cell culture
The human liposarcoma cell lines SW872 and 
SW982 were purchased from the American Type Culture 
Collection (Rockville, MD, USA) in 2013 with certificate 
of analysis. Both the liposarcoma cell lines were cultured 
in RPMI-1640 medium (Life Technologies, Grand 
Island, NY, USA) supplemented with 10% fetal bovine 
serum (Sigma-Aldrich, St. Louis, MO, USA), penicillin 
(100 mg/ml), and streptomycin (100 mg/ml; Invitrogen, 
Grand Island, NY, USA). All cells were maintained in 
a humidified incubator containing 5% CO2–95% air 
atmosphere at 37°C. 
Cell proliferation assay and clonogenic assay 
Cells were exposed to various treatments (DYRK1B 
inhibitor, siRNA, esiRNA, or vehicle control) for respective 
time points as indicated. Cell proliferation ability and 
cytotoxicity of inhibiting DYRK1B were assessed by 3-(4, 
5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide 
(MTT) assays. In brief, liposarcoma cells were seeded at 3 × 
103 cells per well into 96-well plates with complete growth 
medium without antibiotics in triplicate and exposed to 
increasing concentrations (0.01–60 μM) of small molecule 
DYRK1B inhibitor AZ191 (Selleck Chemicals, Houston, 
TX, USA) for five days. Subsequently, 20 μl MTT 
(Sigma-Aldrich, St. Louis, MO, USA) was added to each 
well and then incubated for 4 hours at 37°C and 5% CO2 
humidified atmosphere. Then, the MTT formazan product 
was dissolved with acid isopropanol. The absorbance was 
assessed on a SpectraMax Microplate® Spectrophotometer 
(Molecular Devices LLC, Sunnyvale, CA, USA) at 490 
nm. Liposarcoma cells were seeded at 3 × 103 cells per 
well into 96-well plates in duplicate, and treatment with 
human non-specific siRNA (MISSION® siRNA Universal 
Negative Control, SIC001, Sigma-Aldrich, St. Louis, MO, 
USA) and synthetic human DYRK1B siRNA (Genebank 
Accession Number:NM_004714, coding regions sense 
5′-GGCACUUCAUGUUCCGGAAtt-3′, antisense 
5′-UUCCGGAACAUGAAGUGCCgc-3′, SIHK0641, 
Sigma-Aldrich, St. Louis, MO, USA) or esiRNA human 
DYRK1B (EHU076811, Sigma-Aldrich, St. Louis, 
MO, USA) at concentrations ranging from 10 to 80 nM 
for five days. Cells were imaged on a Nikon Eclipse 
Ti-U microscope (Nikon Corp., Melville, New York, 
USA) equipped with a SPOT RTTM digital camera from 
Diagnostic Instruments, Inc. (MI, USA). For clonogenic 
assay, SW872 and SW982 cells were seeded at 3 × 102 
cells per well into 6-well plates, incubated with AZ191 for 
1–2 weeks, then methanol fixed and Giemsa (GS, Sigma-
Aldrich, St. Louis, MO, USA) stained, followed by colony 
counting. 
Figure 6: Co-incubation of different concentrations of AZ191 with increasing concentrations of doxorubicin increased 
anti-cancer effects in SW872 and SW982 cell lines as determined by the MTT assay. 
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Knockdown of DYRK1B by RNA interference 
DYRK1B knockdown in human liposarcoma 
cells was performed by siRNA or esiRNA transfection. 
The non-specific siRNA oligonucleotides were used 
as negative controls. 2 × 105 liposarcoma cells per well 
were seeded in 12-well plates with complete growth 
medium without antibiotics. Various concentrations (0, 
20, 40, and 60 nM) of DYRK1B siRNA/esiRNA or non-
specific siRNA (40nM) were transfected into cells using 
Lipofectamine RNAiMax Reagent (Invitrogen, CA, 
USA) according to the manufacturer’s instructions. After 
48 hours, transfected cells were subjected to subsequent 
Western blot analysis. 
Protein preparing and western blotting
Protein lysates of the cells were extracted 
with 1× RIPA lysis buffer (Upstate Biotechnology, 
Charlottesville, VA, USA) supplemented with 
complete protease inhibitor cocktail tablets (Roche 
Applied Science, IN, USA) after incubation with 
AZ191 or DYRK1B siRNA/esiRNA for 48 hours. 
The concentrations of the protein were determined by 
protein assay reagents (Sigma-Aldrich, St. Louis, MO, 
USA) with a spectrophotometer (Beckman Du-640, 
Beckman Instruments, Inc., Indianapolis, IN, USA). 
Western blotting was performed as follows: denatured 
proteins were run on NuPAGE® 4–12% Bis-Tris Gel 
(Life Technologies, Grand Island, NY, USA), and then 
transferred to nitrocellulose membrane (Bio-Rad, CA, 
USA). Membranes were blocked in 5% nonfat milk for 
1 hour, and incubated with specific primary antibody 
(rabbit polyclonal antibody to human DYRK1B) or 
mouse monoclonal antibody to human β-actin (Sigma-
Aldrich, St. Louis, MO, USA) at 4°C overnight. 
Following primary antibody incubation, membranes 
were washed with PBST (1×), and goat anti-rabbit 
IRDye® 800CW or goat anti-mouse IRDye® 680LT 
secondary antibody (1:20000 dilution) (926–32211 
and 926–68020, Li-COR Biosciences, NE, USA) was 
added, respectively. Bands were detected using Odyssey 
for Infrared Fluorescent Western Blots from Li-COR 
Bioscience (Lincoln, NE, USA). Quantification analysis 
of Western blot bands was performed with ImageJ 
software (National Institutes of Health, USA). All other 
antibodies used in this study were purchased from Cell 
Signaling Technology (Danvers, MA, USA). 
Figure 7: Model for targeting DYRK1B to regulate cell proliferation and apoptosis in liposarcoma. Inhibition of DYRK1B 
by kinase inhibitor AZ191 or RNAi down-regulation of anti-apoptotic proteins (Bcl-2, p21, and survivin) were observed and are represented. 
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Wound healing assay and cell invasion assay 
Cell migration activity was evaluated by wound 
healing assay. In brief, 2 × 105 cells were seeded onto 
12-well plates and treated with different concentration 
of AZ191, DYRK1B siRNA/esiRNA, or non-specific 
siRNA. After the cells reached 100% confluence, they 
were wounded by scraping three parallel lines with a 200 
µl tip, and then washed three times in serum-free medium 
and incubated in regular medium. Wounds were observed 
at 0, 8, 24, and 48 hours, respectively. Three images were 
taken per well at each time point using a Nikon microscope 
(10× objective) to monitor the cell repair process, and the 
distance between the two edges of the scratch (wound 
width) was measured at three random sites in each image. 
The cell migration distance was calculated by subtracting 
the wound width at each time point from the wound width 
at the 0 hour time point. Transwell invasion chamber assay 
provided an in vitro system to study cell invasion activity 
with a BD BioCoatTM MatrigelTM Invasion Chamber 
(Becton-Dickinson, MA, USA). In brief, cell suspensions 
were prepared containing 5 × 104 cells/well in the upper 
chambers of 24 well invasion chambers with serum-free 
medium, while the bottom chambers were filled with 
750 μl medium with 10% FBS without antibiotics. After 
treatment with DMSO or AZ191 3μM for 48 hours, the 
non-invading cells were carefully scrubbed from the upper 
surface of the membrane with a cotton swab. Cells were 
fixed using 100% methanol, stained in hematoxylin for 
15 min, and rinsed twice in distilled water. The number of 
invading cells was counted in three images per membrane 
under a microscope using a 20× objective. 
Analysis of cell apoptosis by flow cytometry 
Cells were exposed to AZ191 or 0.1% DMSO for 
48 hours and harvested following the manufacturer’s 
protocol. Cells were washed twice with cold PBS and 
then resuspended in 1× Binding Buffer (BD Biosciences, 
San Diego, CA, USA) at a concentration of 1 × 106 cells/
ml. 100 µl of the solution (1 × 105 cells) was transferred 
to a 5 ml culture tube, and 5 µl of FITC Annexin V (BD 
Biosciences, San Diego, CA, USA) was added. Then, 10 
µl Propidium Iodide (PI) (BD Biosciences, San Diego, 
CA, USA) was added, the cells were vortexed, and then 
subsequently incubated for 15 min at room temperature 
(25°C) in the dark. 400 µl of 1× Binding Buffer was added 
to each tube, and the cells were analyzed by flow cytometry 
(BD FACSCalibur, BD Biosciences, San Diego, CA, USA). 
AZ191 in combination with chemotherapy in 
liposarcoma cell lines 
The combination of AZ191 with chemotherapeutic 
drug doxorubicin to liposarcoma cells were assessed by 
MTT assay. SW872 and SW982 cells were seeded into 
96-well plates at a density of 3×103 cells per well in 
triplicate and incubated with a series of concentrations of 
AZ191 and doxorubicin for five days, which was supplied 
by the pharmacy at the Massachusetts General Hospital. 
After five days of co-incubation, cell proliferation was 
determined by the MTT assay as previously described. 
Statistical analysis 
The data were analyzed using Prism 5.0 software 
(Graph Pad Software Inc., San Diego, CA, USA). 
Statistical significance was assessed using Mann-
Whitney test for independent data. One-way ANOVA test 
was performed for multiple comparisons. Associations 
between results of IHC and clinicopathological factors 
were assessed by Chi-square test. Survival analysis was 
performed using Kaplan-Meier survival curves with Log-
rank test for significance. Differences of P < 0.05 were 
considered significant for all statistical tests. 
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